Key Points
- CEO Eric Lefkofsky sold 166,250 shares on Jan. 28 at an average price of $65.56 for proceeds of about $10.9 million, reducing his stake by 1.83% while still holding 8,941,533 shares valued at roughly $586.2 million.
- Tempus beat estimates in its most recent quarter with EPS of $(0.11) vs. consensus $(0.16) and revenue of $334.2 million (up 84.7% year-over-year), but remains unprofitable with a negative net margin (~18.45%) and negative ROE (~73.21%).
- Shares opened at $59.82 and were down about 5.8%; the stock has a $10.64 billion market cap, a high beta (5.22), and a MarketBeat consensus rating of Hold with a $87.20 price target.
Tempus AI, Inc. (NASDAQ:TEM - Get Free Report) CEO Eric Lefkofsky sold 166,250 shares of the firm's stock in a transaction that occurred on Wednesday, January 28th. The shares were sold at an average price of $65.56, for a total transaction of $10,899,350.00. Following the completion of the sale, the chief executive officer directly owned 8,941,533 shares in the company, valued at approximately $586,206,903.48. This trade represents a 1.83% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Tempus AI Stock Down 5.8%
Shares of Tempus AI stock opened at $59.82 on Friday. The company has a quick ratio of 3.12, a current ratio of 3.28 and a debt-to-equity ratio of 2.45. Tempus AI, Inc. has a 52-week low of $36.22 and a 52-week high of $104.32. The company has a market capitalization of $10.64 billion, a P/E ratio of -50.27 and a beta of 5.22. The company has a 50 day moving average of $68.56 and a 200 day moving average of $73.89.
Tempus AI (NASDAQ:TEM - Get Free Report) last released its quarterly earnings data on Tuesday, November 4th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.05. The business had revenue of $334.21 million during the quarter, compared to analysts' expectations of $328.89 million. Tempus AI had a negative net margin of 18.45% and a negative return on equity of 73.21%. The company's revenue for the quarter was up 84.7% on a year-over-year basis. During the same period in the previous year, the company earned ($0.46) EPS. As a group, research analysts forecast that Tempus AI, Inc. will post -6.15 EPS for the current fiscal year.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently modified their holdings of the stock. Cranbrook Wealth Management LLC purchased a new stake in shares of Tempus AI during the third quarter worth approximately $25,000. Concord Wealth Partners increased its stake in Tempus AI by 308.0% in the 2nd quarter. Concord Wealth Partners now owns 408 shares of the company's stock valued at $26,000 after buying an additional 308 shares during the period. JPL Wealth Management LLC purchased a new position in Tempus AI during the 3rd quarter worth $26,000. GAMMA Investing LLC acquired a new stake in shares of Tempus AI in the 3rd quarter worth $28,000. Finally, Allworth Financial LP lifted its stake in shares of Tempus AI by 5,000.0% in the 2nd quarter. Allworth Financial LP now owns 459 shares of the company's stock worth $29,000 after acquiring an additional 450 shares during the period. 24.22% of the stock is currently owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
Several equities analysts have commented on TEM shares. BTIG Research increased their price target on shares of Tempus AI from $96.00 to $105.00 and gave the company a "buy" rating in a research note on Tuesday, November 25th. Canaccord Genuity Group decreased their price objective on shares of Tempus AI from $95.00 to $80.00 and set a "buy" rating for the company in a research note on Monday, December 22nd. Morgan Stanley raised their price objective on Tempus AI from $80.00 to $85.00 and gave the stock an "overweight" rating in a report on Monday, December 1st. Needham & Company LLC boosted their target price on Tempus AI from $70.00 to $100.00 and gave the company a "buy" rating in a report on Wednesday, November 5th. Finally, Piper Sandler decreased their target price on Tempus AI from $105.00 to $80.00 and set a "neutral" rating for the company in a research report on Tuesday, November 11th. Six research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $87.20.
Read Our Latest Stock Analysis on Tempus AI
Tempus AI Company Profile
(
Get Free Report)
Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.
The company's core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
